Canary Capital’s newly launched exchange-traded fund tracking the Injective Protocol (INJ) token has officially commenced trading on the Nasdaq exchange. This financial product marks a significant development in the intersection of traditional finance and digital assets, offering investors regulated exposure to staked digital tokens. According to The Defiant, the fund’s structure is designed to provide a transparent mechanism for accessing the underlying cryptocurrency while adhering to strict regulatory standards.
The investment vehicle focuses specifically on staked INJ, which allows the fund to accumulate yield generated from the blockchain’s validation process. The economic model of the fund involves a specific distribution hierarchy for these generated returns. Before any fees are deducted, the fund is structured to retain a substantial portion of the staking rewards. Specifically, the fund expects to keep 70% of the staking rewards within its portfolio. This retention policy is intended to enhance the fund’s overall performance relative to the underlying asset’s price movements.
Following the retention of staking yields, the fund deducts its operational costs. The primary expense is a separate annual sponsor fee of 1.10%. This fee, along with other miscellaneous administrative expenses, is subtracted from the remaining assets. Investors should note that the net yield they receive will be the staking rewards minus this 1.10% fee and other related charges. The launch on Nasdaq provides a familiar trading environment for institutional and retail investors who may prefer regulated financial instruments over direct cryptocurrency holdings.
This product introduces a new layer of accessibility for those seeking exposure to the Injective ecosystem without managing private keys or dealing with the complexities of direct staking. By listing on a major exchange, the fund aims to bridge the gap between traditional market participants and the growing decentralized finance sector.
